Voyager Therapeutics (NASDAQ:VYGR) Announces Quarterly Earnings Results

Key Points

• EPS beat but revenue miss: Voyager reported adjusted EPS of ($0.47), beating the consensus ($0.54) by $0.07, but revenue was just $1.19 million versus $8.79 million expected, and the company remains unprofitable with a negative ROE (51.35%) and net margin (-296.53%).
• Shares traded down to $3.96 (market cap ~$239 million) with a one-year range of $2.64–$5.55; analysts' consensus is a Moderate Buy with a $16.50 target, though ratings vary from sell to strong-buy.
• Insider selling continued as CEO Alfred Sandrock sold 14,197 shares (~$53,800) and insiders disposed of 61,294 shares over the past three months, with insiders owning 6.39% of the stock.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.07, FiscalAI reports. Voyager Therapeutics had a negative return on equity of 51.35% and a negative net margin of 296.53%.The business had revenue of $1.19 million during the quarter, compared to analysts' expectations of $8.79 million.

Voyager Therapeutics Price Performance

VYGR stock traded down $0.21 on Thursday, reaching $3.96. 459,926 shares of the company traded hands, compared to its average volume of 498,707. Voyager Therapeutics has a one year low of $2.64 and a one year high of $5.55. The company has a market cap of $239.26 million, a P/E ratio of -1.95 and a beta of 1.26. The firm has a fifty day simple moving average of $4.04 and a 200-day simple moving average of $4.06.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on VYGR shares. HC Wainwright reiterated a "buy" rating and issued a $25.00 price objective on shares of Voyager Therapeutics in a report on Tuesday, March 17th. Weiss Ratings reissued a "sell (d-)" rating on shares of Voyager Therapeutics in a research report on Wednesday, April 15th. Truist Financial raised Voyager Therapeutics to a "strong-buy" rating in a research report on Wednesday, March 25th. Finally, Wall Street Zen raised Voyager Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, March 14th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Voyager Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $16.50.

Insiders Place Their Bets

In related news, CEO Alfred Sandrock sold 14,197 shares of the firm's stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $3.79, for a total transaction of $53,806.63. Following the completion of the transaction, the chief executive officer owned 484,060 shares of the company's stock, valued at $1,834,587.40. This trade represents a 2.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders sold 61,294 shares of company stock worth $233,241. 6.39% of the stock is owned by company insiders.

Institutional Trading of Voyager Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Sphera Funds Management LTD. increased its holdings in shares of Voyager Therapeutics by 70.1% in the 4th quarter. Sphera Funds Management LTD. now owns 339,761 shares of the company's stock worth $1,335,000 after purchasing an additional 140,000 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Voyager Therapeutics by 1.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 303,133 shares of the company's stock worth $1,191,000 after purchasing an additional 5,560 shares in the last quarter. Acadian Asset Management LLC increased its holdings in shares of Voyager Therapeutics by 863.3% in the 1st quarter. Acadian Asset Management LLC now owns 230,708 shares of the company's stock worth $778,000 after purchasing an additional 206,758 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of Voyager Therapeutics by 26.7% in the 4th quarter. Wells Fargo & Company MN now owns 132,663 shares of the company's stock worth $521,000 after purchasing an additional 27,964 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Voyager Therapeutics by 28.2% in the 4th quarter. Invesco Ltd. now owns 116,000 shares of the company's stock worth $456,000 after buying an additional 25,522 shares during the last quarter. Institutional investors own 48.03% of the company's stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company's core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm's pipeline includes several AAV-based candidates in preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.